Bausch + Lomb (Rochester, NY), a subsidiary of Valeant Pharmaceuticals International (NYSE:VRX; Laval, QC, Canada), has received FDA clearance for an advanced swept-source optical coherence tomography (OCT) imaging system and updated software for its VICTUS femtosecond laser platform that will provide surgeons with a new, redesigned interface. The interface will allow faster, simpler customized treatment planning to help surgeons improve efficiency and patient-flow during surgical procedures.
Related: Laser cataract surgery: Clearly advanced
The swept-source OCT imaging system allows high-resolution imaging of the entire procedure and can be used to drive incision depth and detail the architecture of arcuate incisions. Together, the new software and imaging system will deliver auto-recognition of key landmarks in the eye, including the pupil, anterior capsule and posterior capsule, along with the capsule tilt compensation to maximize lens fragmentation.
Bausch + Lomb has been installing VICTUS platforms in leading surgery centers globally since it received CE mark in November 2011 and the FDA clearances in July 2012. It is said to be one of the only femtosecond lasers in the U.S. with clearance for the creation of a corneal flap in patients undergoing LASIK surgery, anterior capsulotomy during cataract surgery, penetrating arcuate cuts/incisions in the cornea and laser-assisted lens fragmentation during cataract surgery. The platform has received additional CE marks, including corneal incisions, penetrating keratoplasty, and the creation of intrastromal channel incisions for intracorneal ring segments.
For more information, please visit www.victuslaser.com.
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!